|
|
Article: New breast cancer research from University of Texas described.
- Article from:
- Cancer Weekly
- Article date:
- September 16, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
According to recent research from the United States, "Phosphatidylinositol 3-kinase (Pl3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopybased sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to P13K inhibition in vitro and on outcome after adjuvant tamoxifen."
"PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2positive (22.7%) than in basal-like tumors (8.3%). AKT-1 (1.4%) and PTEN (2.3%) mutations were restricted to ...